Tag: Vaccine
Expert panel in favor of approval to Serum Institute’s cervical cancer...
With the government panel's backing, Serum Institute of India's Quadrivalent Human Papillomavirus vaccine (qHPV) is expected to hit the markets soon
Explained: Ramsay Hunt Syndrome, its cause & symptoms
Dr Anita Mathew, Infectious Disease Specialist, Fortis Hospital, Mulund and Dr Pawan Ojha, Senior Consultant-Neurology, Fortis Hiranandani Hospital, Vashi explain all about Ramsay Hunt...
ICAR launches Covid-19 vaccine for animals
The Ancovax Vaccine on Equines, an inactivated SARS-CoV-2 Delta (COVID-19) vaccine for animals neutralizes both Delta and Omicron variants
Takeda’s dengue vaccine candidate shows positive results during 4.5 years long...
TAK-003 was generally well tolerated, and there were no important safety risks identified. No evidence of disease enhancement was observed over the 54-month follow-up exploratory analysis
Biological E slashes Corbevax price to Rs 250
The reduction in price will result in end users paying a price of ₹400 a dose which will include the taxes and administration charges
Stelis Biopharma seeks PM Modi’s intervention on inability to sell Sputnik...
Bengaluru-based Stelis Biopharma has written to PM Modi requesting for procurement of the jabs due to its inability to sell huge stock of Covid vaccine Sputnik Light
CCMB develops India’s first mRNA based Covid-19 vaccine candidate
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
India committed to accessibility of vaccines for all: S&T Minister
India is working actively with the Global Alliance for Vaccines and Immunization (GAVI), WHO, and the Access to COVID-19 Tools (ACT) Accelerator to realize this goal
Zydus’s two-dose Covid-19 vaccine, ZyCoV-D receives EUA from DCGI
The two-dose regimen has been approved in the age group of 12 years and above
Bharat Biotech’s Covaxin gets emergency approval for 6-12 age group
Covaxin has proven to be safe, well-tolerated, and immunogenic in paediatric subjects in phase II/III study in children 2-18 years of age